Desh Rakshak Aushdhalaya Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Desh Rakshak Aushdhalaya Ltd is ₹ 35 as of 29 May 15:30 . The P/E Ratio of Desh Rakshak Aushdhalaya Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Desh Rakshak Aushdhalaya Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Desh Rakshak Aushdhalaya Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Desh Rakshak Aushdhalaya Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Desh Rakshak Aushdhalaya Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Desh Rakshak Aushdhalaya Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Desh Rakshak Aushdhalaya Ltd

The flagship company Desh Rakshak Aushdhalaya Limited of Bhagwant Group was originally started in 1901 as a Proprietorship Concern by Late Shri Bhagwant Rai Jain, a well renowned Vaidya Father of Late Dr. Paras Kumar Jain.
The Concern was converted into a Private Limited Company in Jul.'94. Desh Rakshakare the oldest manufacturer of Pure Ayurvedic and Herbal Products as discovered by the Ancient Seers & Sages.
The medicines are categorized into Proprietary & Classical Medicines.
They are currently manufacturing around 450 products (Proprietary & Classical mix) and all of these medicines are manufactured as per the prescribed norms and standards of the Indian Government.
The Company was earlier operating the traditional process of manufacturing ayurvedic medicines. Up to 1976, the company producing ethical products of ayurvedic medicines which were supplied to ayurvedic dispensaries.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Desh Rakshak Aushdhalaya Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Desh Rakshak Aushdhalaya Ltd or Sanofi India Ltd?

Market cap of Desh Rakshak Aushdhalaya Ltd is 19 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Desh Rakshak Aushdhalaya Ltd and Sanofi India Ltd?

The stock performance of Desh Rakshak Aushdhalaya Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Desh Rakshak Aushdhalaya Ltd and Sanofi India Ltd?

As of June 14, 2026, the Desh Rakshak Aushdhalaya Ltd stock price is INR ₹35.0. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Desh Rakshak Aushdhalaya Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Desh Rakshak Aushdhalaya Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.